EGFR and cancer: The question arises whether there are additional candidate clinical and/or molecular predictive factors permitting a further selection (‘super-selection’) of patients with EGFR mutated cancers to implement prediction of the awaited TKIs efficacy and identify those patients not beneficiating from TKIs despite the presence of the EGFR alteration.